Filing Flows › BeOne Medicines (ONC) › Capital expenditures
BeOne Medicines (ONC) capital expenditures by quarter
BeOne Medicines' capital expenditures were $35.2M in Q3 2026 (third quarter 2026), +28% from Q2 2026. Over the last 7 quarters it ranged from $27.5M (Q2 2026) to $56.4M (Q1 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $35.2M | +28% | -27% |
| Q2 2026 | $27.5M | -33% | -37% |
| Q1 2026 | $40.8M | +9% | -28% |
| Q4 2025 | $37.5M | -22% | — |
| Q3 2025 | $48.1M | +10% | — |
| Q2 2025 | $43.8M | -22% | — |
| Q1 2025 | $56.4M | — | — |
Q3 2026 at a glance
BeOne Medicines, Q3 2026: revenue $1.9B (+34% year over year), operating margin 22.2%, net earnings $385M, operating cash flow $509M. The chart follows the revenue to costs, profit and cash.
Questions
What is BeOne Medicines' capital expenditures?
BeOne Medicines' capital expenditures were $35.2M in Q3 2026 (third quarter 2026), +28% from Q2 2026.
How has BeOne Medicines' capital expenditures changed?
Over the last 7 quarters it ranged from $27.5M (Q2 2026) to $56.4M (Q1 2025).